Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Regeneron Pharmaceuticals : `s (REGN) RSV Drug Suptavumab Fails NURSERY Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/18/2017 | 11:57am CEST

Regeneron Pharmaceuticals, Inc . REGN announced disappointing results from a phase III study, NURSERY Pre-term on suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV).

The study was initiated in 2015 and completed enrolling patients in the first quarter of 2017. The double-blind, placebo-controlled global study enrolled 1,149 healthy pre-term infants. Patients were randomized in a 1:1:1 ratio to one of the three study groups: suptavumab 30 mg/kg as a single dose; suptavumab 30 mg/kg administered as two doses 8 weeks apart; or placebo. Pre-term infants in the study had a gestational age of less than 36 weeks and were 6 months old or younger at the beginning of the study.

The study did not meet its primary endpoint of preventing medically-attended RSV infections in infants.

The FDA granted Fast Track designation to suptavumab for the prevention of serious lower respiratory tract disease caused by RSV. However, Regeneron plans to discontinue further clinical development of this antibody given the dismal results from the NURSERY study.

We remind investors that the company relies heavily on funding from Sanofi SNY for its immuno-oncology research and development programs. However, Sanofi had earlier decided not to continue the co-development of fasinumab, suptavumab, and trevogrumab.

Regeneron`s stock has gained 28.7% year to date outperforming the industry `s 7.1% rally.

Meanwhile, Regeneron`s second-quarter results were impressive as both earnings and sales beat estimates on the back of strong Eylea sales which grabbed additional market share. Regeneron`s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug`s label for additional indications. The increase in guidance was also encouraging.

Regeneron has co-developed Eylea with the HealthCare unit of Bayer AG BAYRY . The FDA`s approval of Dupixent was a major boost to the company`s portfolio and the company is working to expand its label.

(c) 2017 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
08/18 REGENERON PHARMACEUTICALS : `s (REGN) RSV Drug Suptavumab Fails NURSERY Trial
08/15 TWO FAILED TRIALS : Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) and Regeneron Ph..
08/14DJHot Stocks to Watch in the U.S. and Canada
08/14 REGENERON PHARMACEUTICALS : to Discontinue Development of Suptavumab for Respira..
08/11 REGENERON PHARMACEUTICALS : Baltimore Native Awarded Regeneron Prize for Medical..
08/10 REGENERON PHARMACEUTICALS : Accessing the Regeneron Second Quarter 2017 Financia..
08/10 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Fucosylation..
08/03 REGENERON PHARMACEUTICALS : "Use of a Vegf Antagonist to Treat Angiogenic Eye Di..
08/03 REGENERON PHARMACEUTICALS : Accessing the Regeneron Second Quarter 2017 Financia..
08/03 REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
More news
News from SeekingAlpha
08/17 Evercore ISI initiates 14 bullish calls, 9 neutral
08/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 15, 2017
08/14 Regeneron's suptavumab fails to beat placebo in preventing RSV infection in i..
08/09 Esperion's Triple Combo Hits A Home Run
08/09 Dermira Grabs Big Pharma Castoff
Financials ($)
Sales 2017 5 746 M
EBIT 2017 2 364 M
Net income 2017 1 328 M
Finance 2017 2 375 M
Yield 2017 -
P/E ratio 2017 40,82
P/E ratio 2018 37,06
EV / Sales 2017 8,31x
EV / Sales 2018 7,49x
Capitalization 50 145 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 497 $
Spread / Average Target 6,2%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS27.48%50 145
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
GILEAD SCIENCES0.70%94 170
VERTEX PHARMACEUTICALS101.07%37 346
ACTELION22.00%30 302